Four Companies to Know in Hungary
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Who is Janssen? We’re people; more than 35,000, working hard to treat, cure, stop and prevent some of the most devastating and complex diseases of our time — from diabetes and HIV, to Alzheimer’s and cancer.
Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolism. We are driven to action by the plight of patients, and we aspire to make a positive impact on their lives. That’s why we never limit the search for new medicines to our own four walls—we’re always looking to work with partners interested in helping us achieve our goals.
We stay focused on the disease areas where we believe we can make the biggest difference — oncology, neuroscience, immunology, infectious diseases & vaccines, and cardiovascular & metabolism. But success for us doesn’t stop in our labs.
The world is our lab, and we wouldn’t be able to achieve our success if it weren’t for our approach to collaboration. We work closely with like-minded people from researchers to governments, healthcare professionals to patient organizations. And we work with them at every stage, from early discovery to market access and patient education. Our experts collaborate with external parties at every stage of our value chain—from early discovery to market access. We seek medical breakthroughs wherever they occur. Whether you’re at a university, a research organization, or another biotech or pharmaceutical company, we want to hear from you.
We are Janssen. We collaborate with the world for the health of everyone in it.
Contact
Janssen-Cilag Kft.
H-1123 Budapest
Nagyenyed u. 8-14.
Tel.: + 36 1 884-2858
Fax.: + 36 1 884-2939
e-mail: janssenpharmahu@its.jnj.com
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here
